🇺🇸 FDA
Patent

US 9808505

Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein C receptors (EPCR)

granted A61KA61K31/4439A61K31/5377

Quick answer

US patent 9808505 (Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein C receptors (EPCR)) held by The Board of Regents of the University of Texas System expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/4439, A61K31/5377, A61K38/177, A61K38/191